AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02488291
Drug: 0.25 sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: with different dosage
Trial: NCT02488291
Drug: 0.5µg/ml sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5µg/ml sufentanil
Trial: NCT00106691
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subject takes a placebo tablet identical in appearance to the toremifene 20mg tablet, administered by mouth daily for 360 days.
Trial: NCT00989391
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
Trial: NCT01424423
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00989391
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral twice daily on Days 1-9 and once on Day 10. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
Trial: NCT02594800
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: standard or intensive dose rosuvastatin therapy based on other routine medication for stroke for 52 weeks.
Trial: NCT03353922
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar pill
Trial: NCT01294462
Drug: Acetylsalicylic acid ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Dose ASA
Trial: NCT04342689
Drug: Dietary Supplement containing resistant starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablespoons (\~ 20 grams) to be taken twice daily for 14 days (start with 2 tablespoons once daily for three days, followed by twice daily on days 4 through 14)
Trial: NCT00376805
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: administered intravenously 60 mg/kg days times 2 doses.
Trial: NCT01424423
Drug: GSK1223249
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.V. Infusion
Trial: NCT00928278
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled, 300/150, single dose
Trial: NCT00928278
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled, 300/150, single dose
Trial: NCT00004705
Drug: amiloride
RxNorm normalized name: Amiloride
DrugBank: Amiloride (DB00594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004705
Drug: uridine
RxNorm normalized name: Uridine
DrugBank: Uridine (DB02745)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00953680
Drug: losartan potassium (+) hydrochlorothiazide (HCTZ)
RxNorm normalized name: hydrochlorothiazide / losartan potassium Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose losartan 100 mg/HCTZ 12.5 mg combination tablet in one of two treatment periods.
Trial: NCT04007289
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of placebo ; 2 clinical examinations; blood tests, 3 liver and spleen stiffness measurements, 2 contrast enhanced echocardiographies, 1 hepatic ultrasonography,
Trial: NCT04433559
Drug: Placebo oral tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of placebo in control group
Trial: NCT00633789
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 0 mg, once daily, until progression
Trial: NCT00613080
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1650 mg/m\^2/day orally 5 days/week during radiotherapy.
Trial: NCT00613080
Drug: FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative chemotherapy is administered to all patients who have a complete resection of rectal cancer with negative surgical margins and begins within 4-8 weeks following surgical resection, consisting of a total of 9 14-day cycles. Oxaliplatin 85 mg/m\^2, IV over 2 hours, day 1.~Leucovorin 400 mg/m\^2, IV over 2 hours, day 1. 5-fluorouracil bolus 400 mg/m\^2, IV push, day 1. 5-fluorouracil infusion 2400 mg/m\^2, IV continuous infusion over 46 hours, day 1.
Trial: NCT02845778
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Each sachet contains 0.5 g
Trial: NCT01058512
Drug: NOV-205
RxNorm normalized name: Dallergy Reformulated Nov 2011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There will be 4 treatment Groups with 10 patients in each group:~* Group A: 30 mg NOV-205 daily subcutaneous administration for 49 days~* Group B: 30 mg NOV-205 daily subcutaneous administration for 98 days~* Group C: 60 mg NOV-205 daily subcutaneous administration for 49 days~* Group D: 60 mg NOV-205 daily subcutaneous administration for 98 days
Trial: NCT04642924
Drug: SGM-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorescence-guided surgery
Trial: NCT01705158
Drug: carboplatin and liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin AUC5 and liposomal doxorubicin 40 or 50 mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops.
Trial: NCT03342352
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for epacadostat administered orally twice daily.
Trial: NCT00145691
Drug: Oxcarbazepine
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00049777
Drug: Low molecular weight heparin
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03734029
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered according to label, as one option for Physician's Choice (determined before randomization)
Trial: NCT04890587
Drug: AL8326 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet:10mg/tablet; administered orally once daily in part 1 and part 2, administered orally twice daily for continuous 28-Day cycles in part 3.
Trial: NCT00831701
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo pill per day for 21 days or until stone expulsion
Trial: NCT01605942
Drug: Placebo Drug Delivery System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
Trial: NCT03130426
Drug: iGlarLixi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose is titrated to achieve fasting normoglycemia
Trial: NCT00076336
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine matching placebo or lamivudine matching placebo tablet.
Trial: NCT01382004
Drug: Penicillin-G-benzathine
RxNorm normalized name: Penicillin G Benzathine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening examination: Medical history (emphasis on skin lesions and bone signs) Physical examination.Blood samples for VDRL and TPHA. Clinical safety. Laboratory evaluations: haemoglobin, total WBC count, differential WBC count, platelet count, ALT, AST, urea and creatinine.~Routine assessments: General clinical assessment and physical examination on Days 0 (treatment administered) and 14. Adverse events and concomitant medications (at baseline, Day 14 and in any unscheduled visit). Photograph documentation of skin lesions (at 14 days follow up visit). Follow-up visits performed on 3 and 6 will have a ± 14 days allowable window
Trial: NCT01382004
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Screening examination: Medical history (emphasis on skin lesions and bone signs) Physical examination.Blood samples for VDRL and TPHA. Clinical safety. Laboratory evaluations: haemoglobin, total WBC count, differential WBC count, platelet count, ALT, AST, urea and creatinine.~Routine assessments: General clinical assessment and physical examination on Days 0 (treatment administered) and 14. Adverse events and concomitant medications (at baseline, Day 14 and in any unscheduled visit). Photograph documentation of skin lesions (at 14 days follow up visit). Follow-up visits performed on 3 and 6 will have a ± 14 days allowable window
Trial: NCT03556098
Drug: Glucose-Dependent Insulin-Releasing Hormone[3-30]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of GIP antagonist GIP\[3-30\]
Trial: NCT00823992
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sc once weekly
Trial: NCT02673567
Drug: TEV-48125 - 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration Dose Regimen 1
Trial: NCT02673567
Drug: TEV-48125 - 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration Dose Regimen 2
Trial: NCT02673567
Drug: TEV-48125 - 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration Dose Regimen 3
Trial: NCT02673567
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT03552211
Drug: biotin
RxNorm normalized name: Biotin
DrugBank: Biotin (DB00121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat.
Trial: NCT00919867
Drug: SPD503
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPD503 extended-release 4mg orally administered tablets. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
Trial: NCT00919867
Drug: SPD503 and VYVANSE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPD503 4mg tablets + VYVANSE 50mg capsules orally administered together. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
Trial: NCT01920893
Drug: Placebo (for dupilumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection; Subcutaneous injection.
Trial: NCT01933126
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02181478
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients will receive a single IV dose of 50 mg/kg of cyclophosphamide on day -6
Trial: NCT05735301
Drug: Drug
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: best drug conservative therapy could be uesd in patients who with no indication of surgery
Trial: NCT00002627
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00159913
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral; 3 times a day(TID)
Trial: NCT04453813
Drug: Concurrent chemo-radiotherapy
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~2. IMRT: PTVnx#60.0Gy/27Fr/2.22Gy; PTVnd# 60-64Gy/27Fr/2.22-2.37Gy; PTV1#54Gy/27Fr/2.00Gy
Trial: NCT04364607
Drug: NaCl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive IM NaCl 0.9% as a placebo
Trial: NCT01143051
Drug: epinephrine inhalation aerosol
RxNorm normalized name: epinephrine Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose 220 mcg/inhalation, 10 inhalations
Trial: NCT01143051
Drug: epinephrine inhalation aerosol
RxNorm normalized name: epinephrine Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFA propelled epinephrine inhalation aerosol, 125 mcg/inhalation, 10 inhalations
Trial: NCT01143051
Drug: epinephrine inhalation aerosol
RxNorm normalized name: epinephrine Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFA propelled epinephrine inhalation aerosol, 160 mcg/inhalation, 10 inhalations
Trial: NCT01863134
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02914548
Drug: OPA-15406
RxNorm normalized name: O-PHTHALALDEHYDE 22 g in 4000 mL TOPICAL LIQUID [Safe OPA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were treated with assigned 0.3% or 1% OPA-15406 ointment twice daily.
Trial: NCT02914548
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were treated with assigned 0% OPA-15406 ointment twice daily.
Trial: NCT00225589
Drug: Rosuvastatin calcium
RxNorm normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00872378
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo titrated up to 20mcg BID. (4 weeks at 5mcg BID; 4 weeks at 10mcg BID; 4 weeks at 15mcg BID; 37 weeks at 20mcg BID).
Trial: NCT01731730
Drug: Placebo Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
Trial: NCT01731730
Drug: AYX1 Injection 110 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3mL solution for intrathecal injection with 110 mg of AYX1
Trial: NCT01731730
Drug: AYX1 Injection 330 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3mL solution for intrathecal injection with 330 mg of AYX1
Trial: NCT02404922
Drug: Placebo for CTP-730
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01149486
Drug: Losartan potassium/Hydrochlorothiazide
RxNorm normalized name: losartan potassium/hydrochlorothiazide 100 mg-25 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100/25 mg Tablets
Trial: NCT01149486
Drug: Hyzaar®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100/25 mg Tablets
Trial: NCT00320749
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Will be give on days 8-21
Trial: NCT02283515
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin (RSV) is one of new synthetic, second-generation, sulfur-containing, hydrophilic statin, a highly efficient competitive inhibitors of HMG CoA Reductase having important role in reducing serum cholesterol concentrations and lowers the risk of cardiovascular disease.
Trial: NCT01997814
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in Control Group were treated with scaling and root planing (SRP) along with Placebo therapy, 2 tablets twice daily for 3 weeks.
Trial: NCT01562405
Drug: ACE-011
RxNorm normalized name: dibucaine 0.011 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection every 28 days, dose escalation levels from 15-45 mg
Trial: NCT03067285
Drug: ELV/COBI/FTC/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with ELV/COBI/FTC/TAF during 24 weeks since randomized.
Trial: NCT03067285
Drug: DTG/3TC/ABC + ELV/COBI/FTC/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients continuing on treatment with DTG/3TC/ABC after the randomization for 4 weeks, and then switch to ELV/COBI/FTC/TAF for 24 weeks
Trial: NCT02233244
Drug: CTX-4430
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05782192
Drug: SAL067
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAL067 6mg(2 tablet) and placebo 25mg (1 tablet)
Trial: NCT05782192
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 6mg (2 tablet) and placebo 25mg (1 tablet)
Trial: NCT01680692
Drug: Ropivicaine
RxNorm normalized name: Ropivicaine-Sufentanil Citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of local anesthetic for post-operative analgesia.
Trial: NCT01563289
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 times a day
Trial: NCT01563289
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 times a day
Trial: NCT00663286
Drug: IDP-110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application for 12 weeks
Trial: NCT00663286
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical application for 12 weeks
Trial: NCT00663286
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application for 12 weeks
Trial: NCT01356732
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: From 0 to 0,05 µg/kg to a maximum of 4 µg/kg of sufentanil. 7 minutes before nursing 3 nursing per day during 3 days
Trial: NCT00527020
Drug: GSK1018921
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1018921 will be supplied as 0.5, 5, 10 and 40 milligrams coated tablets.
Trial: NCT00527020
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets will be given to the subjects.
Trial: NCT00167180
Drug: Induction Chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine 25 mg/m2 IV Cyclosphosphamide 60 mg/kg IV
Trial: NCT04149860
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrate for solution for IV infusion
Trial: NCT03935555
Drug: PU-H71
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PU-H71 is a synthetic purine-scaffold stress chaperome inhibitor, which specifically targets HSP90 in the tumor-specific epichaperome
Trial: NCT04311658
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet of placebo vaginally 3 hours prior to LNG-IUD insertion
Trial: NCT02532712
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with same shape and size
Trial: NCT01862835
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02699151
Drug: any drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any drug used for the treatment of SVT (e.g. heparin, low-molecular heparin, non-steroidal anti-inflammatory drug, fondaparinux, vitamin K antagonist)
Trial: NCT03333395
Drug: Nebulized heparin and salbutamol
RxNorm normalized name: salbutamol and budesonide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HS Group medications (study group) (30 patients) which was prepared by adding Heparin 25000 IU in 5ml (5 ampoules of Heparin Sodium 5000 I.U/ML, Nile company for Pharmaceuticals and Chemical Industries-A.R.E.) to Salbutamol 5mg/2.5ml Nebulizer Solution (one Ventolin nebule containing a preservative-free solution of Salbutamol Sulphate BP 2.5mg, GlaxoSmithKline Inc.)
Trial: NCT03968159
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2×placebo tablets \[size- and color-matched to pimavanserin\]) administered orally as a single dose once daily
Trial: NCT00667654
Drug: CNTX-4975
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testing a range of dosing configurations to optimize patient tolerability
Trial: NCT03577392
Drug: oxaliplatin + capecitabine (XELOX chemotherapy)
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin(130mg/m2 over 2h)was intravenously administated for at least 2h on day 1. Capecitabine(1000mg/m2 twice daily)was oral administrated from the evening of day 1 to the morning of day 15.
Trial: NCT00846989
Drug: RKI983A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RKI983 0.05 % twice daily
Trial: NCT00846989
Drug: RKI983A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RKI983 0.1 % twice daily
Trial: NCT01390324
Drug: Fixed-dose combination of naratriptan+naproxen
RxNorm normalized name: combinations of barbiturates
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets containing naratriptan 2,5 mg + naproxen 500 mg
Trial: NCT01390324
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets containing naproxen 500 mg